LUNGevity Welcomes Kristi M. Griffith, MSN, RN, CHPN, HON ONN-CG
04/26/2021 | 08:11am EDT
Send by mail :
Message :
Required fields
WASHINGTON, April 26, 2021 /PRNewswire/ LUNGevity Foundation, the nation s leading lung cancer-focused nonprofit organization, is pleased to announce the hiring of Kristi M. Griffith, MSN, RN, CHPN, HON ONN-CG, as a survivorship navigator.
A nurse navigator with over 30 years of oncology and palliative care experience, Griffith will serve as the first point of contact for patients and families who reach out to the Foundation for support.
She will deliver patient support and comprehensive disease information to lung cancer patients and their families/caregivers along with additional resources to increase lung cancer knowledge and help eliminate barriers to timely and optimal care.
LUNGevity Welcomes Kristi M Griffith, MSN, RN, CHPN, HON ONN-CG prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
previously treated HER2-positive advanced gastric cancer AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
In the US, gastric cancer is most frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving beyond five years.
1,2 Approximately one in five gastric cancers are HER2 positive.
3
The approval by the Food and Drug Administration (FDA) was based on the positive results from the randomised DESTINY-Gastric01 Phase II trial conducted in Japan and South Korea. In the trial, Enhertudemonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and objective respo